Abstract
Dopaminergic mesolimbic and mesocortical systems are fundamental in hedonia and motivation. Therefore their regulation should be central in understanding depression treatment. This review highlights the dopaminergic activity in relation to depressive behavior and suggests two putative receptors as potential targets for research and development of future antidepressants. In this article we review data that describe the role of serotonin in regulating dopamine release, via 5HT2C and 5HT3 receptors. This action of serotonin appears to be linked to depressive-like behavior and to onset of behavioral effects of antidepressants in an animal model of depression. We suggest that drugs or strategies that decrease 5HT2C and increase 5HT3 receptor-mediated dopamine release in the limbic areas of the brain may provide a fast onset of therapeutic effect. Clinical and basic research data supporting this hypothesis are discussed.
Keywords: Animal model of depression, Dopamine, Flinder Sensitive Line rats, Nucleus accumbens, Ventral striatum, Nefazodone, Mirtazapine, Venlafaxine
Current Drug Targets
Title: Modulation of Dopamine Transmission by 5HT2C and 5HT3 Receptors: A Role in the Antidepressant Response
Volume: 7 Issue: 2
Author(s): Eliyahu Dremencov, Yifat Weizmann, Noa Kinor, Iris Gispan-Herman and Gal Yadid
Affiliation:
Keywords: Animal model of depression, Dopamine, Flinder Sensitive Line rats, Nucleus accumbens, Ventral striatum, Nefazodone, Mirtazapine, Venlafaxine
Abstract: Dopaminergic mesolimbic and mesocortical systems are fundamental in hedonia and motivation. Therefore their regulation should be central in understanding depression treatment. This review highlights the dopaminergic activity in relation to depressive behavior and suggests two putative receptors as potential targets for research and development of future antidepressants. In this article we review data that describe the role of serotonin in regulating dopamine release, via 5HT2C and 5HT3 receptors. This action of serotonin appears to be linked to depressive-like behavior and to onset of behavioral effects of antidepressants in an animal model of depression. We suggest that drugs or strategies that decrease 5HT2C and increase 5HT3 receptor-mediated dopamine release in the limbic areas of the brain may provide a fast onset of therapeutic effect. Clinical and basic research data supporting this hypothesis are discussed.
Export Options
About this article
Cite this article as:
Dremencov Eliyahu, Weizmann Yifat, Kinor Noa, Gispan-Herman Iris and Yadid Gal, Modulation of Dopamine Transmission by 5HT2C and 5HT3 Receptors: A Role in the Antidepressant Response, Current Drug Targets 2006; 7 (2) . https://dx.doi.org/10.2174/138945006775515491
DOI https://dx.doi.org/10.2174/138945006775515491 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cholinesterase Inhibitors Modulate Autonomic Function in Patients with Alzheimer´s Disease and Mixed Dementia
Current Alzheimer Research Onconeural Versus Paraneoplastic Antigens?
Current Medicinal Chemistry Acute Cerebral Blood Flow Variations after Human Cardiac Arrest Assessed by Stable Xenon Enhanced Computed Tomography
Current Neurovascular Research Mitochondrial-Associated Metabolic Changes and Neurodegeneration in Huntingtons Disease - from Clinical Features to the Bench
Current Drug Targets The Emerging Role of Stereotactic Radiosurgery in the Treatment of Glioblastoma Multiforme
Current Radiopharmaceuticals From Mice to Macaques – Animal Models of HIV Nervous System Disease
Current HIV Research Neuropsychological Findings in Obsessive-Compulsive Disorder and its Potential Implications for Treatment
Current Psychiatry Reviews EDITORIAL (Thematic Issue: New Targets of Medical Treatment in Psychiatric Disorders)
Current Neuropharmacology Curcumin and its Multi-target Function Against Pain and Inflammation: An Update of Pre-clinical Data
Current Drug Targets Phosphodiesterase: An Interface Connecting Cognitive Deficits to Neuropsychiatric and Neurodegenerative Diseases
Current Pharmaceutical Design Endothelins Role in the Control of the Acute Phase of Trypanosoma cruzi Infection
Mini-Reviews in Medicinal Chemistry Understanding Stem Cell-Mediated Brain Repair Through Neuroimaging
Current Stem Cell Research & Therapy Brain Norepinephrine System as a Target for Antidepressant and Mood Stabilizing Medications
Current Drug Targets Genetic Data Supporting the NMDA Glutamate Receptor Hypothesis for Schizophrenia
Current Pharmaceutical Design Magnetic Resonance Imaging in the Encephalopathic Term Newborn
Current Pediatric Reviews New Frontiers in Alcoholism and Addiction Treatment
Recent Patents on CNS Drug Discovery (Discontinued) Catatonia: A Narrative Review
Central Nervous System Agents in Medicinal Chemistry Dopaminergic Enhancement of Cognitive Function
Current Pharmaceutical Design A New Combined Therapeutic Strategy of Governor Vessel Electro-Acupuncture and Adult Stem Cell Transplantation Promotes the Recovery of Injured Spinal Cord
Current Medicinal Chemistry Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease
Current Neuropharmacology